Detalles de la búsqueda
1.
Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models.
Int J Mol Sci
; 21(12)2020 Jun 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32599852
2.
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.
Hepatology
; 60(5): 1697-707, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24996197
3.
Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
Am J Hematol
; 84(10): 657-60, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19731393
4.
An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma.
Clin Lymphoma Myeloma
; 8(3): 140-5, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18650176
5.
Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Clin Adv Hematol Oncol
; 6(10): 755-60, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18997666
6.
Narrowband (312-nm) UV-B suppresses interferon gamma and interleukin (IL) 12 and increases IL-4 transcripts: differential regulation of cytokines at the single-cell level.
Arch Dermatol
; 139(2): 155-61, 2003 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-12588221
7.
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
Clin Cancer Res
; 17(16): 5299-310, 2011 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21622725
Resultados
1 -
7
de 7
1
Próxima >
>>